Medicenna TherapeuticsÂ Corp (MDNA)

Name: Medicenna TherapeuticsÂ Corp (MDNA) Share Price Today, Stock Analysis, Annual Report | Value Research
Brand: Medicenna TherapeuticsÂ Corp (MDNA)

Stock Card

$0.31

$0.00 (0.30%)

As on 03-Jan-2024 09:30EDT

Market cap

$11 Mln

Revenue (TTM)

$0 Mln

P/E Ratio

P/B Ratio

1.4

Div. Yield

0 %

Value Research Rating

Quality Score

Growth Score

Valuation Score

Momentum Score

Know more

Explore 5 star rated stocks

Medicenna TherapeuticsÂ Corp (MDNA) Share Price

Compare

High: Low: Return:

Price P/E Ratio P/B Ratio

Stock Range

Today’s Range

Low: 0.30 High: 0.31

52 Week Range

Low: -- High: --

Liquidity

Low Moderate High

Fundamentals

Net Profit (TTM)

$0 Mln
ROE

-0.4 %
ROCE

-- %
Industry P/E

--
EV/EBITDA

-1
Debt to Equity

--
Book Value

$--
EPS

$-0.2
Face value

--
Shares outstanding

69,637,504

10 Years Aggregate

CFO

CA$-88.55 Mln

EBITDA

CA$-90.21 Mln

Net Profit

CA$-67.73 Mln

Company	YTD	1 Month	3 Months	1 Year	3 Years	5 Years	10 Years
Medicenna TherapeuticsÂ Corp (MDNA)	0.3	-6.9	9.2	-33.3	-59.7	-10.0	--
BSE Sensex^*	-9.6	-2.7	2.9	-5.0	5.4	5.7	10.4
S&P Small-Cap 600^#	-5.8	-5.3	-13.7	-6.3	5.3	3.0	5.5

As on 03-Jan-2024 | *As on 04-Sep-2026 | #As on 26-Oct-2023

Company	2023	2022	2021	2020	2019	2018
Medicenna TherapeuticsÂ Corp (MDNA)	-33.4	-71.9	-65.2	80.0	401.7	-67.4
S&P Small-Cap 600	13.9	-17.4	25.3	9.6	20.9	-9.7
BSE Sensex	18.7	4.4	22.0	15.8	14.4	5.9

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details

Key Ratios

View Details

Shareholding Pattern

View Details

About Medicenna TherapeuticsÂ Corp (MDNA)

Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. It develops MDNA55, an interleukin- 4 (IL-4) EC for the... treatment of recurrent glioblastoma, as well as for brain tumors. The company also develops MDNA11, an enhanced version of IL-2 to activate and proliferate the immune cells needed to fight cancer; MDNA209, an IL-2 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host disease; MDNA413, a dual IL-4/IL-13 antagonist to treat cancer immunotherapies; and MDNA132, an IL-13 Superkine for solid tumors. In addition, it provides BiSKITs platform to develop designer Superkines by fusing them to other proteins, antibodies, cytokines, or other Superkines. The company is headquartered in Toronto, Canada. Read more

Founder, Chairman, Pres & CEO

Dr. Fahar Merchant Ph.D.
Founder, Chairman, Pres & CEO

Dr. Fahar Merchant Ph.D.
Headquarters

Toronto, ON
Website

https://www.medicenna.com

FAQs for Medicenna TherapeuticsÂ Corp (MDNA)

What is the current share price of Medicenna TherapeuticsÂ Corp (MDNA) Today?

The share price of Medicenna TherapeuticsÂ Corp (MDNA) is $0.31 (NASDAQ) as of 03-Jan-2024 09:30 EDT. Medicenna TherapeuticsÂ Corp (MDNA) has given a return of -59.73% in the last 3 years.

What is the current PB & PE ratio of Medicenna TherapeuticsÂ Corp (MDNA)?

Since, TTM earnings of Medicenna TherapeuticsÂ Corp (MDNA) is negative, P/E ratio is not available.
The P/B ratio of Medicenna TherapeuticsÂ Corp (MDNA) is 1.40 times as on 03-Jan-2024, a 54 discount to its peers’ median range of 3.07 times.

PE & PB ratio at the end of financial year.

Year	P/E Ratio	P/B Ratio
2023	28.30	1.49
2022	-3.14	3.41
2021	-12.40	5.58
2020	-11.35	2.61
2019	-3.39	6.09

What is the 52 Week High and Low of Medicenna TherapeuticsÂ Corp (MDNA)?

The 52-week high and low of Medicenna TherapeuticsÂ Corp (MDNA) are Rs -- and Rs -- as of 06-Sep-2026.

What is the market cap of Medicenna TherapeuticsÂ Corp (MDNA)?

Medicenna TherapeuticsÂ Corp (MDNA) has a market capitalisation of $ 11 Mln as on 03-Jan-2024. As per SEBI classification, it is a Small Cap company.

Should I invest in Medicenna TherapeuticsÂ Corp (MDNA)?

Before investing in Medicenna TherapeuticsÂ Corp (MDNA), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.

For guidance, explore our expert-curated portfolios and Stock recommendations with Value Research Stock Advisor.

Want to explore on your own? Click here to see how this stock scores on quality, growth, valuation, and momentum.